Estrella Immunopharma, Inc. ESLA
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -10.62% | 12.09% | 15.46% | 37.18% | -1.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.92% | 26.43% | 47.67% | 53.12% | 65.19% |
| Operating Income | 18.92% | -26.43% | -47.67% | -53.12% | -65.19% |
| Income Before Tax | 17.08% | -26.43% | -47.67% | -53.12% | -65.19% |
| Income Tax Expenses | -100.00% | -47.06% | -47.06% | -37.50% | -37.50% |
| Earnings from Continuing Operations | 17.09% | -26.41% | -47.65% | -53.10% | -65.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.09% | -26.41% | -47.65% | -53.10% | -65.16% |
| EBIT | 18.92% | -26.43% | -47.67% | -53.12% | -65.19% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 23.98% | -22.46% | -46.55% | -51.70% | 82.69% |
| Normalized Basic EPS | 23.98% | -22.46% | -46.49% | -51.74% | 82.69% |
| EPS Diluted | 23.98% | -22.46% | -46.55% | -51.70% | 82.69% |
| Normalized Diluted EPS | 23.98% | -22.46% | -46.49% | -51.74% | 82.69% |
| Average Basic Shares Outstanding | 10.43% | 5.45% | 1.84% | 1.64% | 33.82% |
| Average Diluted Shares Outstanding | 10.43% | 5.45% | 1.84% | 1.64% | 33.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |